{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:46:36Z","timestamp":1792179996721,"version":"4.4.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0201"],"award-info":[{"award-number":["W81XWH-17-1-0201"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0202"],"award-info":[{"award-number":["W81XWH-17-1-0202"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["1P01HL131481-01A1"],"award-info":[{"award-number":["1P01HL131481-01A1"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["1R01DK122456-01A1"],"award-info":[{"award-number":["1R01DK122456-01A1"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["1R24DK103032"],"award-info":[{"award-number":["1R24DK103032"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["5P01HL146367"],"award-info":[{"award-number":["5P01HL146367"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["5R01DK109675"],"award-info":[{"award-number":["5R01DK109675"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["5R01HL132516"],"award-info":[{"award-number":["5R01HL132516"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016027","name":"NYU Grossman School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.atherosclerosis.2023.117304","type":"journal-article","created":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T20:45:10Z","timestamp":1695242710000},"page":"117304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["RAGE\/DIAPH1 and atherosclerosis through an evolving lens: Viewing the cell from the \u201cInside \u2013 Out\u201d"],"prefix":"10.1016","volume":"394","author":[{"given":"Ravichandran","family":"Ramasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Shekhtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8902-070X","authenticated-orcid":false,"given":"Ann Marie","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.117304_bib1","article-title":"The RAGE\/DIAPH1 axis: mediator of obesity and proposed biomarker of human cardiometabolic disease","author":"Arivazhagan","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094579","article-title":"The RAGE\/DIAPH1 signaling Axis & implications for the pathogenesis of diabetic complications","volume":"23","author":"Ramasamy","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib3","doi-asserted-by":"crossref","DOI":"10.20900\/immunometab20210024","article-title":"Inflammation meets metabolism: roles for the receptor for advanced glycation end products Axis in cardiovascular disease","volume":"3","author":"Senatus","year":"2021","journal-title":"Immunometabolism"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11886-021-01504-4","article-title":"Diabetes and cardiovascular complications: the epidemics continue","volume":"23","author":"L\u00f3pez-D\u00edez","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib5","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/2012","article-title":"Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts","volume":"4","author":"Park","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib6","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1161\/01.CIR.0000039325.03698.36","article-title":"RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice","volume":"106","author":"Bucciarelli","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib7","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jconrel.2021.09.012","article-title":"P-selectin targeted RAGE-shRNA lipoplexes alleviate atherosclerosis-associated inflammation","volume":"338","author":"Mocanu","year":"2021","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib8","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2337\/db07-1808","article-title":"Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes","volume":"57","author":"Soro-Paavonen","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib9","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/CIRCRESAHA.109.201103","article-title":"Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice","volume":"106","author":"Bu","year":"2010","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1042\/CS20140045","article-title":"Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis","volume":"127","author":"Koulis","year":"2014","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cvr\/cvp036","article-title":"RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice","volume":"82","author":"Sun","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib12","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1365-2362.2011.02514.x","article-title":"Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression","volume":"41","author":"Morris-Rosenfeld","year":"2011","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1172\/JCI32703","article-title":"Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-\/- mice","volume":"118","author":"Harja","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5387\/fms.2019-12","article-title":"Integral role of receptor for advanced glycation end products (RAGE) in nondiabetic atherosclerosis","volume":"65","author":"Uekita","year":"2019","journal-title":"Fukushima J. Med. Sci."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib15","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s10020-022-00431-6","article-title":"Dendritic cell-mediated chronic low-grade inflammation is regulated by the RAGE-TLR4-PKC\u03b2(1) signaling pathway in diabetic atherosclerosis","volume":"28","author":"Zhao","year":"2022","journal-title":"Mol Med"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib16","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","article-title":"Effect of two intensive statin regimens on progression of coronary disease","volume":"365","author":"Nicholls","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib18","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2337\/db10-0778","article-title":"Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice","volume":"60","author":"Parathath","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0022-4804(03)00039-8","article-title":"Mouse model of heterotopic aortic arch transplantation","volume":"111","author":"Chereshnev","year":"2003","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137289","article-title":"RAGE impairs murine diabetic atherosclerosis regression and implicates IRF7 in macrophage inflammation and cholesterol metabolism","volume":"5","author":"Senatus","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib21","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M801465200","article-title":"Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42","volume":"283","author":"Hudson","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib22","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1074\/jbc.M111.277731","article-title":"Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1","volume":"287","author":"Rai","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4161\/21541248.2014.973765","article-title":"FHOD proteins in actin dynamics--a formin' class of its own","volume":"5","author":"Bechtold","year":"2014","journal-title":"Small GTPases"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/MOH.0000000000000099","article-title":"The regulatory role of serum response factor pathway in neutrophil inflammatory response","volume":"22","author":"Taylor","year":"2015","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib25","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.str.2016.06.021","article-title":"Change in the molecular dimension of a RAGE-ligand complex triggers RAGE signaling","volume":"24","author":"Xue","year":"2016","journal-title":"Structure"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbamem.2018.10.015","article-title":"Diaphanous-1 affects the nanoscale clustering and lateral diffusion of receptor for advanced glycation endproducts (RAGE)","volume":"1861","author":"Zhu","year":"2019","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib27","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/CIRCRESAHA.111.262519","article-title":"Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways","volume":"110","author":"Tour\u00e9","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ebiom.2017.11.012","article-title":"The formin, DIAPH1, is a key modulator of myocardial ischemia\/reperfusion injury","volume":"26","author":"O'Shea","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib29","doi-asserted-by":"crossref","first-page":"F1601","DOI":"10.1152\/ajprenal.00075.2018","article-title":"Deletion of the formin Diaph1 protects from structural and functional abnormalities in the murine diabetic kidney","volume":"315","author":"Manigrasso","year":"2018","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s42003-023-04643-2","article-title":"DIAPH1 mediates progression of atherosclerosis and regulates hepatic lipid metabolism in mice","volume":"6","author":"Senatus","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib31","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/31729","article-title":"Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase","volume":"393","author":"Arber","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0962-8924(01)02008-6","article-title":"How is actin polymerization nucleated in vivo?","volume":"11","author":"Condeelis","year":"2001","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib33","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/31735","article-title":"Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization","volume":"393","author":"Yang","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12967-015-0685-8","article-title":"Cofilin1 is involved in hypertension-induced renal damage via the regulation of NF-\u03baB in renal tubular epithelial cells","volume":"13","author":"Wang","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib35","doi-asserted-by":"crossref","first-page":"21047","DOI":"10.1074\/jbc.M109.016444","article-title":"Essential role of cofilin-1 in regulating thrombin-induced RelA\/p65 nuclear translocation and intercellular adhesion molecule 1 (ICAM-1) expression in endothelial cells","volume":"284","author":"Fazal","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0092-8674(03)00278-2","article-title":"Actin dynamics control SRF activity by regulation of its coactivator MAL","volume":"113","author":"Miralles","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/srep22450","article-title":"Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction","volume":"6","author":"Manigrasso","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf7084","article-title":"Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice","volume":"13","author":"Manigrasso","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib39","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1161\/01.ATV.0000249630.02085.12","article-title":"Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes","volume":"26","author":"Cuccurullo","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib40","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.bbadis.2011.05.007","article-title":"Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products","volume":"1812","author":"Feng","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib41","doi-asserted-by":"crossref","first-page":"F528","DOI":"10.1152\/ajprenal.00127.2010","article-title":"The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse","volume":"299","author":"Giunti","year":"2010","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib42","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1055\/s-0031-1283148","article-title":"Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1","volume":"43","author":"Ishibashi","year":"2011","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib43","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1194\/jlr.M038968","article-title":"Statins stimulate the production of a soluble form of the receptor for advanced glycation end products","volume":"54","author":"Quade-Lyssy","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbrc.2009.05.061","article-title":"Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation","volume":"385","author":"Matsui","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1124\/jpet.105.095125","article-title":"Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model","volume":"317","author":"Wang","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib46","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3892\/mmr.2014.3113","article-title":"Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells","volume":"11","author":"Di","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib47","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00395-009-0071-x","article-title":"Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor","volume":"105","author":"Ihm","year":"2010","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib48","first-page":"1142","article-title":"Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway","volume":"22","author":"Zhou","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib49","first-page":"6121","article-title":"Pioglitazone attenuates atherosclerosis in diabetic mice by inhibition of receptor for advanced glycation end-product (RAGE) signaling","volume":"23","author":"Gao","year":"2017","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejps.2011.03.011","article-title":"Peroxisome proliferator-activated receptor \u03b4 downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice","volume":"43","author":"Liang","year":"2011","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib51","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.3892\/mmr.2017.6978","article-title":"Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice","volume":"16","author":"Li","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/dom.15226","article-title":"Cardiovascular prevention with glucose-lowering drugs in type 2 diabetes: an evidence-based approach to the categories of primary and secondary prevention","author":"Mannucci","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108503","article-title":"A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy","volume":"249","author":"Ashfaq","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib54","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2147\/DDDT.S418321","article-title":"SGLT1: a potential drug target for cardiovascular disease","volume":"17","author":"Zhao","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib55","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121654","article-title":"Canagliflozin attenuates thioacetamide-induced liver injury through modulation of HMGB1\/RAGE\/TLR4 signaling pathways","volume":"322","author":"Abdelmageed","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13098-022-00886-x","article-title":"New insights into the role of empagliflozin on diabetic renal tubular lipid accumulation","volume":"14","author":"Sun","year":"2022","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib58","first-page":"3625","article-title":"Renoprotection of dapagliflozin in human renal proximal tubular cells via the inhibition of the high mobility group box 1-receptor for advanced glycation end products-nuclear factor-\u03baB signaling pathway","volume":"18","author":"Yao","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.06.011","article-title":"Soluble RAGEs - prospects for treating & tracking metabolic and inflammatory disease","volume":"72","author":"Schmidt","year":"2015","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib61","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1042\/bj20021371","article-title":"Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury","volume":"370","author":"Yonekura","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/s-0033-1363423","article-title":"Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality","volume":"23","author":"Prasad","year":"2014","journal-title":"Int. J. Angiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib63","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2337\/db13-1636","article-title":"RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice","volume":"63","author":"Song","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib64","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.celrep.2019.06.061","article-title":"A receptor of the immunoglobulin superfamily regulates adaptive thermogenesis","volume":"28","author":"Hurtado Del Pozo","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib65","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/oby.23774","article-title":"Pharmacological antagonism of receptor for advanced glycation end products signaling promotes thermogenesis, healthful body mass and composition, and metabolism in mice","volume":"31","author":"Wilson","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib66","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1161\/01.ATV.0000160342.20342.00","article-title":"Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men","volume":"25","author":"Falcone","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib67","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1001\/archneur.62.11.1734","article-title":"Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia","volume":"62","author":"Emanuele","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib68","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2119\/2006-00090.Nakamura","article-title":"Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes","volume":"13","author":"Nakamura","year":"2007","journal-title":"Mol Med"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib69","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/dmrr.766","article-title":"Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes","volume":"24","author":"Nakamura","year":"2008","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib70","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.freeradbiomed.2007.06.017","article-title":"Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins","volume":"43","author":"Santilli","year":"2007","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib71","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3132\/dvdr.2008.031","article-title":"Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients","volume":"5","author":"Katakami","year":"2008","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib72","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.atherosclerosis.2008.08.026","article-title":"Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes","volume":"204","author":"Katakami","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1055\/s-0031-1278352","article-title":"Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients","volume":"18","author":"McNair","year":"2009","journal-title":"Int. J. Angiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.metabol.2008.10.020","article-title":"Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients","volume":"58","author":"Nakamura","year":"2009","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib75","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.atherosclerosis.2009.06.003","article-title":"Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease","volume":"207","author":"Mahajan","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib76","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.atherosclerosis.2009.08.031","article-title":"Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes","volume":"209","author":"Tam","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib77","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/j.1365-2362.2009.02212.x","article-title":"High plasma levels of the soluble receptor for advanced glycation endproducts in patients with symptomatic carotid atherosclerosis","volume":"39","author":"Basta","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib78","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.atherosclerosis.2009.12.029","article-title":"Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis","volume":"210","author":"Basta","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib79","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.2215\/CJN.03360410","article-title":"Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients","volume":"5","author":"Nakashima","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib80","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/clc.20815","article-title":"Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention","volume":"33","author":"McNair","year":"2010","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib81","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.atherosclerosis.2011.05.023","article-title":"Association of increased S100B, S100A6 and S100P in serum levels with acute coronary syndrome and also with the severity of myocardial infarction in cardiac tissue of rat models with ischemia-reperfusion injury","volume":"217","author":"Cai","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib82","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.atherosclerosis.2011.08.003","article-title":"Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy","volume":"219","author":"Jeong","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib83","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2011.07.115","article-title":"Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis","volume":"220","author":"Kim","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib84","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.atherosclerosis.2011.11.008","article-title":"Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography","volume":"220","author":"Yang","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib85","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.atherosclerosis.2012.10.050","article-title":"Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients","volume":"226","author":"Piarulli","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib86","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1177\/030006051204000527","article-title":"Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects","volume":"40","author":"Kotani","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib87","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.atherosclerosis.2013.01.016","article-title":"Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes","volume":"227","author":"Fujisawa","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib88","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1472-6823-13-32","article-title":"Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients","volume":"13","author":"Motawi","year":"2013","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib89","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/nep.12166","article-title":"Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels","volume":"18","author":"Kim","year":"2013","journal-title":"Nephrology"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib90","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1155\/2013\/129360","article-title":"Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation","volume":"35","author":"Falcone","year":"2013","journal-title":"Dis. Markers"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib91","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/584504","article-title":"Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease","author":"Falcone","year":"2013","journal-title":"Sci. World J."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib92","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.03.025","article-title":"Comparison of effects of pioglitazone and glimepiride on plasma soluble RAGE and RAGE expression in peripheral mononuclear cells in type 2 diabetes: randomized controlled trial (PioRAGE)","volume":"234","author":"Koyama","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib93","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.05.037","article-title":"Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE","volume":"23","author":"Moriya","year":"2014","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib94","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2337\/dc14-1435","article-title":"Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function","volume":"38","author":"Kajikawa","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib95","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jdiacomp.2014.11.008","article-title":"sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study","volume":"29","author":"Al Rifai","year":"2015","journal-title":"J. Diabet. Complicat."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib96","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2015.02.015","article-title":"Serum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS)","volume":"240","author":"Hudson","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128452","article-title":"Genetics of plasma soluble receptor for advanced glycation end-products and cardiovascular outcomes in a community-based population: results from the atherosclerosis risk in communities study","volume":"10","author":"Maruthur","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib98","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-015-0292-2","article-title":"Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study","volume":"14","author":"Heier","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib99","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1210\/jc.2015-4069","article-title":"Low endogenous secretory receptor for advanced glycation end-products levels are associated with inflammation and carotid atherosclerosis in prediabetes","volume":"101","author":"Di Pino","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/pr.2016.55","article-title":"Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks","volume":"80","author":"Rowisha","year":"2016","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib101","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s10753-016-0367-6","article-title":"Soluble levels of receptor for advanced glycation endproducts (RAGE) and progression of atherosclerosis in individuals infected with human immunodeficiency virus: ACTG NWCS 332","volume":"39","author":"Danoff","year":"2016","journal-title":"Inflammation"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib102","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0035-1570754","article-title":"Atherosclerosis and the hypercholesterolemic AGE-RAGE Axis","volume":"25","author":"McNair","year":"2016","journal-title":"Int. J. Angiol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib103","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1373\/clinchem.2016.264135","article-title":"Cross-sectional analysis of AGE-CML, sRAGE, and esRAGE with diabetes and cardiometabolic risk factors in a community-based cohort","volume":"63","author":"Loomis","year":"2017","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib104","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2017.08.015","article-title":"Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease","volume":"266","author":"Reichert","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib105","article-title":"Metabolic dysfunction in Emirati subjects in Abu Dhabi: relationship to levels of soluble RAGEs","volume":"16","author":"Abdulle","year":"2019","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib106","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosis.2019.05.020","article-title":"The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event","volume":"287","author":"Grauen Larsen","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib107","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4528382","article-title":"The relationship between plasma soluble receptor for advanced glycation end products and coronary artery disease","author":"Wang","year":"2019","journal-title":"Dis. Markers"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib108","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015261","article-title":"Pathological role of receptor for advanced glycation end products in calcified aortic valve stenosis","volume":"9","author":"Saku","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12944-020-01397-2","volume":"19","author":"Melin","year":"2020","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib110","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcjd.2021.01.004","article-title":"Association between soluble receptor for advanced glycation end product and endogenous secretory soluble receptor for advanced glycation end product levels and carotid atherosclerosis in diabetes: a systematic review and meta-analysis","volume":"45","author":"Wang","year":"2021","journal-title":"Can. J. Diabetes"},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib111","doi-asserted-by":"crossref","DOI":"10.1177\/14791641221085269","article-title":"Plasma advanced glycation end products and soluble receptor for advanced glycation end products as indicators of sterol content in human carotid atherosclerotic plaques","volume":"19","author":"Pinto","year":"2022","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib112","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12933-022-01535-3","article-title":"Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study","volume":"21","author":"Sabbatinelli","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2023.117304_bib113","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2023.02.005","article-title":"Emerging markers of inflammation and oxidative stress as potential predictors of coronary artery disease","volume":"376","author":"Tsirebolos","year":"2023","journal-title":"Int. J. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023052255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023052255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T11:57:37Z","timestamp":1723723057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023052255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":113,"alternative-id":["S0021915023052255"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117304","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RAGE\/DIAPH1 and atherosclerosis through an evolving lens: Viewing the cell from the \u201cInside \u2013 Out\u201d","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.117304","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117304"}}